ToF-SIMS imaging has been drawing attention due to the wide range of applications in the biological and biomedical fields. These applications include the acquisition of quantitative and qualitative data that ranges in scale from single cells to organs, image visualisation and interpretation of biomarkers for diagnosis and development of pharmaceutics. This study focused on molecular imaging of mouse brain tissue sections using cluster primary ion beams. First, cluster ion beams were applied to comparative background studies of biomolecules and brain total lipid extract. Enhancement of the secondary ion signal was observed using water-containing cluster primary ion beams, especially for [M+H]+ type secondary ions. Water-containing clusters were then used to acquire ToF-SIMS images from the cerebellar area of serial mouse brain tissue sections. Again, water-containing cluster beams produced the highest secondary ion yields in both grey and white matter, gaining a new level of insight into the lipid compositions of both types of tissue in the brain. A clinical case was also evaluated with ToF-SIMS imaging, using cluster beams for the analysis of 3xTg-AD mouse brain tissue. SIMS images were registered with fluorescence microscopy images for the in situ identification and co-localisation of the Amyloid-β plaques on the SIMS images. Spectra from regions of interest were analysed to identify possible ion fragments derived from the Aβ protein. The co-localisation of cholesterol was also studied from images obtained with different primary ion beams. The results presented show that cluster ToF-SIMS can be successfully applied to brain tissue imaging. New primary ion beam technologies allow us to acquire data with more useful secondary ion yield for clinical applications and biological research. Nevertheless, future technological improvements are required for specialised applications e.g. cellular imaging. Moreover, processing the data obtained is still challenging and more data processing tools are also needed for interpretation.

Doctor of Philosophy / Department of Chemistry / Duy H. Hua / Three research projects were carried out and they are described below. The synthesis of substituted phenolic compounds including halogenated di- and trihydroxybenzenes, aminophenols, and substituted di-tert-butylphenols are described. Redox potentials of the synthesized molecules along with various known laccase substrates were measured, and an inverse relationship between the oxidation potential and the efficiency of oxidation by laccase of halogenated hydroxybenzenes and aminophenols is demonstrated. The synthesized substituted phenols were found to be substrates but not inhibitors of laccase. We discovered a new class of di-tert-butylphenols compounds that inhibits the growth of mosquito larvae at low concentrations. Compound 17, 2,4-di-tert-butyl-6-(3-methyl-2-butenyl) phenol caused greater than 98% mortality of third-instar larvae of Anopheles gambiae in the concentration of 0.18 µM. These compounds do not inhibit laccases. It appears that they affect a new target of the mosquito that is different from those of currently existing pesticides. Two anti-Alzheimer molecules, CP2 and TP70, discovered in our laboratory were studied for their pharmacokinetics and distribution. The distribution of CP2 and TP70 in mouse brain region and various tissues of mice were examined. HPLC analysis revealed that CP2 treatment in primary neurons accumulates in mitochondria fraction. Similarly, the amount of CP2 in the brain tissue from wild type and APP/PS1 mice treated with 25 mg/kg/daily for 2 months also have the highest concentration in the mitochondria fractions in the hippocampus. The results show that CP2 and TP70 can penetrate the blood brain barrier and accumulate in the tissue in significant amounts. Pharmacokinetics and bioavailability of compound TP70 were determined. Area under the curve and bioavailability value F were calculated, and data show that TP70 has a good PK profile and bioavailability. For the preparation of a novel tripeptidyl norovirus 3C-like protease (3CL[superscript]pro) inhibitor, the P3 unnatural amino acid, (S)-3-hydroxyphenylalanine was synthesized. The P3 is designed to increase the polarity with the addition of the alcohol group. After combining the P3 unnatural amino acid with the P1 and P2 to form the novel tripeptidyl compound, a study comparing the relations between the structure and its activity (SAR) will confirm whether prediction is correct in our pursuit for an antiviral therapeutic drug in the form of a protease inhibitor.

<p>Mice have become the preferred model system for studying brain function and disease. With the powerful genetic tools available, mouse models can be created to study the underlying molecular basis of neurobiology in vivo. Just as magnetic resonance imaging is the dominant tool for evaluating the human brain, high-resolution MRI--magnetic resonance microscopy (MRM)--is a useful tool for studying the brain of mouse models. However, the need for high spatial resolution limits the signal-to-noise ratio (SNR) of the MRM images. To address this problem, T1-shortening contrast agents can be used, which not only improve the tissue contrast-to-noise ratio (CNR) but also increase SNR by allowing the MR signal to recover faster between pulses. By "actively staining" the tissue with these T1-shortening agents, MRM can be performed with higher resolution, greater contrast, and shorter scan times. In this work, active staining with T1-shortening agents was used to enhance three types of in vivo mouse brain MRM: (1) angiographic imaging of the neurovasculature, (2) anatomical imaging of the brain parenchyma, and (3) functional imaging of neuronal activity.</p> <p></p> <p>For magnetic resonance angiography (MRA) of the mouse, typical contrast agents are not useful because they are quickly cleared by the body and/or extravasate from the blood pool before a high-resolution image can be acquired. To address these limitations, a novel contrast agent--SC-Gd liposomes--has been developed, which is cleared slowly by the body and is too large to extravasate from the blood pool. In this work, MRA protocols were optimized for both the standard technique (time-of-flight contrast) and SC-Gd liposomes. When the blood was stained with SC-Gd liposomes, small vessel CNR improved to 250% that of time-of-flight. The SC-Gd liposomes could also be used to reduce scan time by 75% while still improving CNR by 32%.</p> <p>For MRM of the mouse brain parenchyma, active staining has been used to make dramatic improvements in the imaging of ex vivo specimens. However for in vivo imaging, the blood-brain barrier (BBB) prevents T1-shortening agents from entering the brain parenchyma. In this work, a noninvasive technique was developed for BBB opening with microbubbles and ultrasound (BOMUS). Using BOMUS, the parenchyma of the brain could be actively stained with the T1-shortening contrast agent, Gd-DTPA, and MRM images could be acquired in vivo with unprecedented resolution (52 x 52 x 100 micrometers3) in less than 1 hour.</p> <p>Functional MRI (fMRI), which uses blood oxygen level dependant (BOLD) contrast to detect neuronal activity, has been a revolutionary technique for studying brain function in humans. However, in mice, BOLD contrast has been difficult to detect and thus routine fMRI in mice has not been feasible. An alternative approach for detecting neuronal activity uses manganese (Mn2+). Mn2+ is a T1-shortening agent that can enter depolarized neurons via calcium channels. Thus, Mn2+ is a functional contrast agent with affinity for active neurons. In this work, Mn2+ (administered with the BOMUS technique) was used to map the neuronal response to stimulation of the vibrissae. The resultant activation map showed close agreement to published maps of the posterior-lateral and anterior-medial barrel field of the primary sensory cortex.</p> <p>The use of T1-shortening agents to actively stain tissues of interest--blood, brain parenchyma, or active neurons--will facilitate the use of MRM for studying mouse models of brain development, function, and disease.</p> / Dissertation

Alzheimer’s Disease, also called AD, is a horrible, degenerative brain disease that more than 35 million people over the world have. Today, there is no cure for this disease, only treatments that are temporarily relieving the symptoms. The two proteins that is thought to be the main cause of AD is amyloid β (Aβ) and tau. Previously, people have tried studying Aβ in vivo using green fluorescent protein fusion together with Aβ. However, this is difficult since the aggregation of Aβ will lead to loss of fluorescence. This study aimed to crystallize the fusion protein mNG-A β1-42 and to investigate its properties as a molecular fluorescent Aβ-amyloid specific probe. Dynamic light scattering (DLS) was used to confirm that the majority of the protein was not in the form of soluble aggregates. The DLS experiments were followed by several rounds of crystallization trials. Initial screening and the subsequent narrowing down of potential conditions where mNG-Aβ1-42 could form crystals. Several staining experiments were conducted as well, including staining brain tissue from mouse with both Swedish and Arctic mutation, from human patients with sporadic AD and from human patients with AD with the Arctic mutation. The DLS experiments showed that the protein used in the crystallization experiments mostly consisted of molecular particles of the same radius. However, there was clear evidence of some larger species present that could have been a potential problem for crystallization. Crystallization experiments suggested that PEG 8000 was the most promising precipitant amongst other conditions identified for crystallization of mNG-Aβ1-42. However, the study was ultimately unsuccessful in developing crystals of sufficient high quality for diffraction studies to commence. The staining experiments demonstrated that mNG-Aβ1-42 could bind both by itself and with another amyloid probe, Congo red, and with antibodies in brain tissue from mouse with both Swedish and Arctic mutation, from human patients with sporadic AD and from human patients with AD with the Arctic mutation. In conclusion, several characteristics of mNG-Aβ1-42 were revealed in this study.

No description available.

Foram imunizados 27 macacos-prego (Cebus apella), por via intramuscular, com vacina anti-rábica inativada, produzida a partir de cérebros de camundongos lactentes (VARCCL), empregada nas campanhas de prevenção da raiva animal de cães e gatos. Os animais permaneceram em cativeiro, durante o período de junho de 1995 a junho de 1997, sendo divididos em 3 grupos experimentais e vacinados conforme o esquema: grupo I, com 3 doses a intervalo de 30 dias; o II, com 2 doses a intervalo 30 dias e reforço aos 210 dias; e, o III com uma dose e reforço aos 210 dias. A revacinação anual foi realizada em todos os animais aos 365 dias. As amostras de soros foram obtidas aos 0, 30, 60, 90, 150, 210, 240, 300, 365, 395, 545 e 730 dias, e armazenadas à temperatura de -20ºC, e a dosagem dos anticorpos realizada através do teste simplificado da inibição da fluorescência. Verificou-se que os animais do grupo I apresentaram soroconversão mais duradoura (12232 dias) do que os dos grupos II e III (p<0,05) após a vacinação inicial, e os animais do grupo I apresentaram soroconversão mais duradoura (183,6120,6 dias) do que os dos grupos II (p<0,05), após a revacinação anual aos 365 dias. A VARCCL induziu a resposta imune nos macacos-prego, após vacinação e revacinação, respectivamente, em 81,4 por cento e 76,0 por cento dos animais; com produção de anticorpos neutralizantes, iguais ou superiores a 0,5 UI/ml, porém, de curta duração; não constituindo assim, imunógeno apropriado para ser utilizado na rotina de imunização destes animais de difícil lide, mantidos em cativeiro / Twenty-seven capuchin monkeys (Cebus apella) were intramuscularly immunized with inactivated suckling mouse brain rabies vaccine (SMBV) employed in campaigns for animal rabies prevention in dogs and cats. The animals were kept confined from June, 1995 to June, 1997. They were divided into 3 experimental groups and vaccinated according to the following scheme: group I, with 3 doses within a 30-day interval; group II, with 2 doses within a 30-day interval and a booster dose at the 210th day; and, group III; with a single dose and a booster dose at the 210th day. All animals were given the annual re-vaccination at the 365th day. Sera samples were obtained at the 0th, 30 th, 60th, 90 th, 150 th, 210 th, 240 th, 300 th, 365 th, 395 th, 545 th e 730 th days and kept stored at 20ºC. The antibodies dosage was carried out through the simplified inhibition fluorescent test. The following results were observed: animals belonging to group I had longer humoral immune response (12232 days) than the ones belonging either to group II or group III (p<0.05) after initial vaccination; animals of group I presented longer humoral immune response (183.6120.6 days) than the ones of the group II (p<0.05) after the annual re-vaccination at the 365th day. The SMBV induced humoral immune response in capuchin monkeys after vaccination and re-vaccination in respectively 81.4 per cent and 76.0 per cent of the animals, producing neutralizing antibodies equal to or higher than 0.5 IU/ml; however, they were short-lasting, being therefore not appropriate as an immunogen to be used routinely in the immunization of these animals which are difficult both to be deal with and to be held confined

Foram imunizados 27 macacos-prego (Cebus apella), por via intramuscular, com vacina anti-rábica inativada, produzida a partir de cérebros de camundongos lactentes (VARCCL), empregada nas campanhas de prevenção da raiva animal de cães e gatos. Os animais permaneceram em cativeiro, durante o período de junho de 1995 a junho de 1997, sendo divididos em 3 grupos experimentais e vacinados conforme o esquema: grupo I, com 3 doses a intervalo de 30 dias; o II, com 2 doses a intervalo 30 dias e reforço aos 210 dias; e, o III com uma dose e reforço aos 210 dias. A revacinação anual foi realizada em todos os animais aos 365 dias. As amostras de soros foram obtidas aos 0, 30, 60, 90, 150, 210, 240, 300, 365, 395, 545 e 730 dias, e armazenadas à temperatura de -20ºC, e a dosagem dos anticorpos realizada através do teste simplificado da inibição da fluorescência. Verificou-se que os animais do grupo I apresentaram soroconversão mais duradoura (12232 dias) do que os dos grupos II e III (p<0,05) após a vacinação inicial, e os animais do grupo I apresentaram soroconversão mais duradoura (183,6120,6 dias) do que os dos grupos II (p<0,05), após a revacinação anual aos 365 dias. A VARCCL induziu a resposta imune nos macacos-prego, após vacinação e revacinação, respectivamente, em 81,4 por cento e 76,0 por cento dos animais; com produção de anticorpos neutralizantes, iguais ou superiores a 0,5 UI/ml, porém, de curta duração; não constituindo assim, imunógeno apropriado para ser utilizado na rotina de imunização destes animais de difícil lide, mantidos em cativeiro / Twenty-seven capuchin monkeys (Cebus apella) were intramuscularly immunized with inactivated suckling mouse brain rabies vaccine (SMBV) employed in campaigns for animal rabies prevention in dogs and cats. The animals were kept confined from June, 1995 to June, 1997. They were divided into 3 experimental groups and vaccinated according to the following scheme: group I, with 3 doses within a 30-day interval; group II, with 2 doses within a 30-day interval and a booster dose at the 210th day; and, group III; with a single dose and a booster dose at the 210th day. All animals were given the annual re-vaccination at the 365th day. Sera samples were obtained at the 0th, 30 th, 60th, 90 th, 150 th, 210 th, 240 th, 300 th, 365 th, 395 th, 545 th e 730 th days and kept stored at 20ºC. The antibodies dosage was carried out through the simplified inhibition fluorescent test. The following results were observed: animals belonging to group I had longer humoral immune response (12232 days) than the ones belonging either to group II or group III (p<0.05) after initial vaccination; animals of group I presented longer humoral immune response (183.6120.6 days) than the ones of the group II (p<0.05) after the annual re-vaccination at the 365th day. The SMBV induced humoral immune response in capuchin monkeys after vaccination and re-vaccination in respectively 81.4 per cent and 76.0 per cent of the animals, producing neutralizing antibodies equal to or higher than 0.5 IU/ml; however, they were short-lasting, being therefore not appropriate as an immunogen to be used routinely in the immunization of these animals which are difficult both to be deal with and to be held confined

No description available.

Since the first human spaceflight in 1961, hundreds of humans have been in space. Microgravity and high radiation are the main spaceflight hazards. The space environment is known to impact several aspects of human health, such as bone density and cognitive performance. However, the effects of long­duration spaceflights on a cellular and molecular level, utilizing biosamples and multiomic approaches, is poorly studied. In this project, the method Spatial Transcriptomics has been utilized to compare brain tissue from the hippocampus region of mice that have been in space with a control group of mice that have stayed on Earth. Spatial Transcriptomics allow for the quantification of gene expression, while maintaining the spatial information of the transcriptome. The results of this study suggest that spaceflights cause mitochondrial stress.   This thesis work is part of a more extensive study in collaboration with NASA, and more studies will be conducted to investigate the effects of spaceflights further. If these findings are confirmed, medicines used on Earth to treat patients with mitochondrial dysfunction could increase the well­being of astronauts in space. / Sedan den första människan skickades till rymden år 1961, har hundratals astronauter lämnat jordens atmosfär.   De mest signifikanta hälsoriskerna i rymden är mikrogravitation och hög strålning och rymdmiljön har stor påverkan på oss. Exempelvis upplever astronauter ofta minskad benmassa och nedsatt kognitiv funktion. Men kunskapen kring hur människor påverkas av långtidresor i rymden är begränsad. Särskilt få experiment har genomförts på stora dataset från biologiska prover, på en molekylär och cellulär nivå. I detta projekt har genuttryck hos möss som varit i rymden jämförts med en kontrollgrupp av möss som stannat på jorden. Metoden Spatial Transcriptomics (ST) har använts för att undersöka vävnadssnitt från hippocampus i mushjärna. Med ST är det möjligt att undersöka RNA­molekyler och kartlägga deras position i vävnaden. Resultatet från denna studie indikerar att miljön i rymden leder till dysfunktion i mitokondrierna. Detta arbete är en del av en större studie i samarbete med NASA och fler experiment kommer genomföras för att undersöka hur vi påverkas av miljön i rymden. Om fler studier stödjer detta resultat, kan mediciner som använts på jorden för att behandla patienter med dysfunktion i mitokondrierna, användas i förebyggande syfte för astronauter.

La barrière hémato-encéphalique (BHE) est une structure retrouvée au niveau des capillaires cérébraux. Elle représente un véritable obstacle pour les actifs qui doivent se rendre au cerveau pour y exercer un effet pharmacologique. Durant les étapes du développement du médicament, des modèles cellulaires in vitro sont utilisés pour l’évaluation de la perméabilité au cerveau des nouveaux médicaments. Le modèle assemblé avec des cellules endothéliales (CEs) isolées des capillaires des cerveaux de souris présente un intérêt particulier pour la recherche en raison de sa facilité d’obtention et sa pertinence pour le criblage des médicaments. Le but de ce projet a été de construire et de caractériser un modèle monocouche de CEs primaires de souris. En parallèle, un modèle monocouche de la lignée murine b.End3 a été investigué. L’évaluation de ces modèles a été basée sur les valeurs de TEER et de perméabilité aux marqueurs fluorescents, ainsi que sur la présence des protéines spécifiques de la BHE. La validation du modèle a été établie par la corrélation des résultats de perméabilité obtenus avec le modèle développé (in vitro) avec ceux obtenus chez la souris (in vivo). L’intégrité et l’expression des protéines spécifiques de la BHE du modèle primaire se sont montrées supérieures au modèle bEnd.3. La corrélation in vitro/in vivo du modèle primaire a abouti à un r2 = 0,765 comparé au r2 = 0,019 pour le modèle bEnd.3. Ce travail de recherche montre que le modèle primaire monocouche issu de cellules endothéliales cérébrales de souris est un modèle simple et fiable pour la prédiction de la perméabilité des actifs à travers la BHE. / The blood-brain barrier (BBB), a central nervous system structure, is found in the cerebral capillaries. It represents a major obstacle for the drugs that have to reach the brain in order to exercise their pharmacological effect. In the early stages of the drug development, in vitro cell models are used to evaluate the brain permeability of new drugs. Models assembled using primary endothelial cells (ECs) isolated from mouse brain capillaries are of particular interest for research, as for their ease of obtaining and relevance for the drug screening. Thus, the goal of this project was to build and characterize a primary mouse monolayer model. At the same time, a murine b.End3 cell line monolayer model was investigated. The evaluation of these models was based on the TEER and fluorescent marker permeability values, as well as on the presence of the BBB hallmark proteins. The model validation was established by the correlation of the permeability data obtained with the in vitro model and the data obtained in mice (in vivo). As a result, the primary mouse model showed superior monolayer integrity and higher expression of the tight junction and membrane transporter proteins when compared with the bEnd.3 cell line model. The in vitro/in vivo correlation of the primary model resulted in r2 = 0.765 compared to the bEnd.3 model with r2 = 0.019. This research work shows that the primary monolayer mouse model is a simple and reliable model for predicting the drug permeability across the BBB.